


**Meet the Network and Community Leadership**  
**Network: Development, Regulatory, & Outcomes (DRO)**  
**Community: Global Health (GH)**



**Community Vice Chair:**  
**Terrence Blaschke, MD**  
**Stanford University and**  
**Bill and Melinda Gates**  
**Foundation**

Terrence F. Blaschke, MD, is Professor of Medicine and Molecular Pharmacology (Emeritus) at Stanford University, Adjunct Professor of Bioengineering and Therapeutic Sciences at UCSF and Adjunct Professor of Medicine at Indiana University. Dr. Blaschke received his medical degree from Columbia University and did his residency training in Internal Medicine at UCLA. Following fellowship training in Clinical Pharmacology at the University of California, San Francisco, he joined the faculty at Stanford University School of Medicine in 1974.

Dr. Blaschke is a past president of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). He is the recipient of the Rawls-Palmer award, the Henry W. Elliott award and the Oscar B. Hunter award from ASCPT. He has been a consultant and past Chair of the Generic Drugs Advisory Committee of the US FDA and a member of the Nonprescription Drugs Advisory Committee. He chaired the Drug Utilization Review Panel of The U.S. Pharmacopeial Convention (USP) from 1995-2000. He served on the Board of Directors of Therapeutic Discovery Corporation of Palo Alto, Crescendo Pharmaceuticals, in Mountain View, California and is now a member of the board of directors of DURECT Corporation in Cupertino, California. From November 2012 through 2015 Dr. Blaschke was a Senior Program Officer/Senior Advisor at the Bill and Melinda Gates Foundation in Seattle, WA, and is now a consultant to the BMGF. Dr. Blaschke is and has been a consultant to a number of pharmaceutical firms.

In terms of his scientific expertise, he was a member of the AIDS Clinical Trials Group (ACTG) at its inception, and served as chair of the Pharmacology Committee and as a member of the Executive Committee of the ACTG. His research has primarily involved clinical trials, with a focus on sources of variability in drug response in different therapeutic areas, including HIV, TB and other chronic diseases. Studies of variability have emphasized modeling exposure-response (PK/PD) relationships. His recent clinical efforts, supported by the BMGF, are directed at improving patient adherence in TB and other chronic diseases. His involvement in clinical trials and with the pharmaceutical industry has also led to a strong interest in approaches to improve the efficiency of the drug development process. Dr. Blaschke has over 180 original publications in peer reviewed journals. He has served on a number of editorial boards and is an Associate Editor of the Annual Review of Pharmacology and Toxicology.